Predictive value of non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio for in-stent restenosis after drug-eluting stent implantation in patients with coronary heart disease. [PDF]
Tuersun T +3 more
europepmc +1 more source
Lowering low-density lipoprotein cholesterol levels in patients with type 2 diabetes mellitus
Harold E Bays Louisville Metabolic and Atherosclerosis Research Center, Louisville, KY, USA Abstract: Type 2 diabetes mellitus (T2DM) is characterized by hyperglycemia, insulin resistance, and/or progressive loss of β-cell function.
Bays HE
core
Prediction of LVEF improvement in patients with HFrEF and HFmrEF following treatment with Sacubitril/Valsartan. Workflow of this study investigating the functional capacity improvement in response to Sacubitrail/Valsartsan in a real‐world scenario of heart failure treatment.
Florian Appenzeller +8 more
wiley +1 more source
Association of non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio (NHHR) with cardiovascular mortality in peritoneal dialysis patients: a prospective cohort study. [PDF]
Zhang Y +7 more
europepmc +1 more source
A contemporary simple risk score for prediction of severe AKI after HT. Abstract Background The aim of this study was to develop a simple risk score to estimate severe acute kidney injury (AKI) risk based on a large contemporary heart transplantation (HT) cohort.
Shuangshuang Zhu +10 more
wiley +1 more source
Abstract Aims The prognostic significance of left ventricular (LV) diastolic dysfunction (LVDD) severity in patients with dilated cardiomyopathy (DCM) remains uncertain. This study aimed to evaluate the association of LVDD severity and elevated left atrial pressure (eLAP) with patient outcomes in stable, non‐acutely decompensated patients with DCM ...
Mateusz Winiarczyk +12 more
wiley +1 more source
Patients with type 1 diabetes mellitus and recommended low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol and apolipoprotein B targets - a SwissDiab study. [PDF]
Liu C +4 more
europepmc +1 more source
Dapagliflozin alleviates high‐fat‐induced obesity cardiomyopathy by inhibiting ferroptosis
Abstract Aim: Dapagliflozin (Dapa) is a novel hypoglycaemic agent with multiple cardiovascular protective effects, and it is widely used in treatment of heart failure patients, but whether it can improve obese phenotype of heart failure and its mechanism is still unclear.
Di Chen +7 more
wiley +1 more source
Abstract Aims Inflammation plays a critical role in both the development and progression of heart failure (HF), which is a leading cause of morbidity and mortality worldwide. However, the causality between specific inflammation‐related proteins and HF risk remains unclear.
Xian‐Guan Zhu +9 more
wiley +1 more source
Association between non-high-density lipoprotein cholesterol to high-density lipoprotein cholesterol ratio (NHHR), atherogenic index of plasma and acute ischemic stroke classified by CISS. [PDF]
He Z, Lv M, Luo J, Li Q, Zhang Z, Niu X.
europepmc +1 more source

